Lauren Spitzinger, NP
Acute Care · Denver, CONPI 1649462151
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Sanofi at 59.0% of the total. Reporting peaked in 2024 at $6,262 and has fallen 56.7% since, to $2,713 in 2025. Among acute care clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $169.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$7K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$1K
- Amgen$123
- Pulmonx Corporation$78
- plus $129 from 4 others
What the payments were for
- Consulting fees$6,82254%
- Travel & lodging$2,01516%
- Food & beverage$3,69229%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 13 | $7,398 |
| GSK | 11 | $1,972 |
| Regeneron Healthcare Solutions, Inc. | 23 | $1,614 |
| AstraZeneca | 18 | $1,215 |
| Amgen | 1 | $123 |
| Pulmonx Corporation | 1 | $78 |
| Viatris Specialty LLC | 1 | $59 |
| Boehringer Ingelheim | 3 | $44 |
| Genentech USA, Inc. | 2 | $14 |
| LEO Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,529 in reported general payments places this provider in the 95th percentile of 239 acute care providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $56,790 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $47,384 |
| Spiriva RespimatTiotropium Bromide | 42 | $31,684 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $15,752 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $13,392 |
| DuleraMometasone/Formoterol | 32 | $12,578 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $12,402 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,024 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $7,320 |
| Atrovent HfaIpratropium Bromide | 15 | $6,734 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,725 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $5,867 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $2,230 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,929 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta | $1,972 | $75,535111 claims |
| Boehringer IngelheimSpiriva Respimat | $44 | $31,68442 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $1,215 | $29,14457 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 239 acute care providers in Colorado.
Other acute care in Denver
- Robert WorleyDenver$4K
- Abigail KoehlerDenver$3K
- Emily ZeszutekDenver$2K
- Elizabeth BrzyckiDenver$1K
- Whitney AndersonDenver$1K
- Tiffany MorganColorado Springs$590K
- Wendy StevensCortez$57K
- Peter ByrneLone Tree$56K
- Paige YountColorado Springs$26K
- Sarah NorwoodColorado Springs$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.